Benefits
Anxiety with mild stimulating profile (Russian indication)
Russian approval for anxiety states. UNIQUE mechanism: GABA prodrug providing anxiolysis WITHOUT typical sedation due to niacin moiety's vasodilatory/stimulating effects. Mechanism: in CNS, cleaved to release GABA (anxiolytic) + niacin (vasodilator/possibly mild stimulant). Distinct from benzodiazepines (sedating) and from selank (peptide). Less rigorous evidence base than other Russian anxiolytics.
Cerebrovascular disease and cerebral circulation
Russian indication for cerebrovascular insufficiency and chronic cerebral ischemia. Mechanism: niacin component provides vasodilation enhancing cerebral blood flow. Used in older Russian clinical practice for elderly cognitive complaints related to cerebrovascular insufficiency. Limited rigorous clinical evidence outside Russian/CIS literature.
Mild depression / asthenic depression
Approved Russian indication for asthenic depression and chronic fatigue with depressive component. Combined GABA + niacin mechanism may provide both anxiolysis and mild activation. Limited rigorous Western RCT evidence.
GABA prodrug delivery (mechanism advantage)
Distinguishing pharmacological feature: Picamilon is GABA PRODRUG. Pure GABA cannot cross BBB efficiently. Niacin component provides lipophilicity for BBB penetration; once in CNS, amide bond cleaved by amidases to release GABA + nicotinic acid. Mechanism design rationale similar to phenibut (phenyl-GABA) but with niacin's additional vasodilatory and metabolic effects.
Migraine prophylaxis (limited Russian evidence)
Used in Russia for migraine prophylaxis based on theoretical cerebrovascular benefits. Limited rigorous evidence; not first-line treatment in any modern guidelines outside Russian clinical practice.
Mechanism of action
GABA prodrug — CNS amidase cleavage
Picamilon is N-nicotinoyl-GABA — synthetic conjugate cleaved in CNS by amidase enzymes to release: (1) GABA — inhibitory neurotransmitter providing anxiolytic effects via GABA-A receptor activation; (2) NICOTINIC ACID (niacin) — vasodilator with vitamin B3 activity. Dual delivery mechanism distinguishes from pure GABA-mimetic compounds.
Niacin vasodilation enhancing cerebral blood flow
Niacin component provides vasodilation — enhances cerebral blood flow and microcirculation. Mechanism for cerebrovascular insufficiency indications. Less prominent than direct GABA effects but contributes to overall pharmacology.
GABA-A receptor activation (post-cleavage)
Released GABA acts at GABA-A receptors providing anxiolysis. Less potent than direct GABA-A modulators (benzodiazepines) but more selective due to local CNS GABA release vs peripheral effects.
Modest BBB penetration via lipophilic conjugate
Amide-bonded niacin-GABA conjugate is more lipophilic than free GABA — crosses BBB. Once in CNS, cleaved to active components. Mechanism design similar to other prodrug strategies.
Clinical trials
Russian-language clinical studies in cerebrovascular insufficiency and cognitive disorders (multiple Russian publications, 1980s-1990s).
Russian patients with cerebrovascular insufficiency, chronic cerebral ischemia, asthenic disorders, anxiety states with autonomic features.
Russian clinical evidence supports use for cerebrovascular and anxiety conditions. Limited Western methodological scrutiny due to Russian-language predominance. Mechanism via GABA + niacin dual delivery. Approved Russian regulatory use since 1969 launch.
Russian preclinical/clinical pharmacology study (Silkina IV, Gan'shina TC, Seredin SB, Mirzoian RS 2005, Eksp Klin Farmakol 68(1):20-24, PMID 15786959).
Comparative pharmacology study of GABAergic mechanisms — afobazole (fabomotizole) and picamilon — in cerebrovascular and neuroprotective effects.
Picamilon demonstrated GABAergic cerebrovascular and neuroprotective effects. Mechanistic confirmation of GABA-mediated CNS effects via prodrug delivery. Foundational comparative evidence for picamilon's place in Russian neuropharmacology.
FDA Warning Letters issued November 2015 to multiple supplement companies marketing picamilon.
Supplement companies marketing picamilon as dietary supplement in US.
FDA DETERMINED picamilon NOT a legal dietary ingredient — declared synthetic drug rather than natural compound (vitamin, herb, or other DSHEA-eligible substance). Many companies removed picamilon products following warning letters. IMPORTANT REGULATORY HISTORY — distinguishes picamilon from other Russian peptides as NOT eligible for US dietary supplement marketing despite continued sales by some vendors. Demonstrates regulatory uncertainty for Russian-developed compounds in US market.
About this ingredient
Picamilon (N-nicotinoyl-γ-aminobutyric acid, nicotinoyl-GABA, pikamilon; brand name PIKAMILON) is a SYNTHETIC CONJUGATE of NIACIN (nicotinic acid, vitamin B3) and GABA (γ-aminobutyric acid) — developed in USSR in 1969 by Soviet pharmaceutical research as a GABA PRODRUG capable of BBB penetration. Subsequently studied in Russia and Japan. CHEMISTRY: amide bond between niacin's carboxylic acid and GABA's amino group — lipophilic enough to cross BBB but cleaved in CNS by amidase enzymes to release: (1) GABA — inhibitory neurotransmitter providing anxiolytic effects via GABA-A activation; (2) NIACIN — vasodilator with B3 vitamin activity.
DUAL DELIVERY mechanism creates unique pharmacology — anxiolytic + mild vasodilator + niacin metabolic effects. RUSSIAN REGULATORY APPROVAL: anxiety, depression with asthenic component, cerebrovascular insufficiency, chronic cerebral ischemia, migraine prophylaxis, alcohol withdrawal adjunct. Multi-indication approval reflects extensive Russian clinical use.
PHARMACOLOGY: short half-life; multiple daily doses needed; onset 1-2 hours. UNIQUE compared to other GABA-mimetics: COMBINED anxiolytic + mild stimulating profile due to niacin component (most GABAergics are pure sedatives). FDA REGULATORY STATUS: 2015 — FDA issued WARNING LETTERS to multiple supplement companies marketing picamilon as dietary supplement, determining it is NOT a legal dietary ingredient (synthetic drug rather than natural compound or vitamin per DSHEA standards).
Many companies removed products. Significant US regulatory history distinguishing picamilon from other Russian peptides — explicitly NOT supplement-eligible in US. Some online vendors continue selling as 'research compound' but US marketing is regulatory gray zone with explicit FDA disagreement.
Russian-language clinical literature dominates; limited rigorous Western RCTs. EVIDENCE: 1/5 reflects: (1) Russian regulatory approval since 1969 for multiple indications, (2) Mirzoian 2005 PMID 15786959 mechanistic GABAergic study, (3) FDA 2015 NEGATIVE regulatory determination as not supplement-eligible, (4) limited rigorous Western RCT evidence, (5) Russian-language literature accessibility limitations, (6) clear GABA prodrug mechanism, (7) dual GABA + niacin delivery distinct pharmacology. SAFETY: Generally well-tolerated; better profile than phenibut (no documented dependence concerns); FDA does not consider legal dietary supplement in US.
Best positioned as: (a) ANXIETY with mild stimulating profile in Russia under medical supervision, (b) CEREBROVASCULAR insufficiency adjunct (Russian indication, limited Western evidence), (c) GABA PRODRUG ALTERNATIVE for those wanting GABA delivery without phenibut's dependence liability, (d) NOT recommended for US dietary supplement use due to FDA regulatory determination, (e) RESEARCH COMPOUND status in US warrants regulatory caution, (f) limited rigorous Western evidence — most Russian clinical research not subject to Western methodological standards. Honest framing: picamilon is a unique GABA prodrug with dual GABA + niacin delivery — interesting pharmacology with Russian clinical history but limited rigorous Western RCT evidence. The 2015 FDA regulatory determination explicitly classifies picamilon as NOT a legal dietary ingredient in the US — important context for US consumers.
Better safety profile than phenibut (no dependence concerns documented). Reasonable for Russian medical use under prescription; explicitly problematic for US supplement market following FDA action.